Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | EDNRB | P24530 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | MAP2 | P11137 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | USP8 | P40818 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957017 | 0.90 | SERPINE1 (0.54) | PTPN5MAP2SERPINE1MAPT | |
| SCHEMBL3958387 | 0.90 | SERPINE1 (0.49) | ACLYMAP2SERPINE1 | |
| SCHEMBL4069649 | 0.88 | SERPINE1 (0.56) | KITMAP2SERPINE1MAPTFFAR4 | |
| SCHEMBL4133133 | 0.88 | HIF1A (0.53) | PTPN2PTPN1PTPN5ERAP1KIT | |
| SCHEMBL4072264 | 0.86 | EDNRB (0.46) | ACLYPTPN2PTPN1PTPN5ERAP1 | |
| SCHEMBL4137805 | 0.84 | CNR1 (0.40) | ACLYPTPN2PTPN1PTPN5ERAP1 | |
| SCHEMBL4137808 | 0.84 | CNR1 (0.40) | ACLYPTPN2PTPN1PTPN5ERAP1 | |
| SCHEMBL13910226 | 0.83 | SERPINE1 (0.51) | PTPN5MAP2SERPINE1MAPT | |
| SCHEMBL4142121 | 0.83 | MAP2 (0.54) | PTPN5MAP2SERPINE1MAPT | |
| SCHEMBL3955112 | 0.82 | MAP2 (0.60) | MAP2SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036906-A1 | Azaindoles as inhibitors of soluble adenylate cyclase | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | claimed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2036906-A1 | Azaindoles as inhibitors of soluble adenylate cyclase | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2036906-A1 | Azaindoles as inhibitors of soluble adenylate cyclase | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009030725-A2 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | ADCY1, ADCY5, ADCY2 | ACLY 3063/4885PTPN2 1240/4885PTPN1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.